ESMO 2023 | The future of the TAR-210 delivery system for erdafitinib in NMBIC

Antoni Vilaseca, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential clinical applications of TAR-210, a bladder-inserted drug delivery system designed to provide local, continuous release of erdafitinib in patients with non-muscle invasive bladder cancer (NMIBC). The novel delivery system was found to be safe, where low grade events were predominantly reported. TAR-210 consequently may benefit patients with high-risk disease and reduce the need for surgical intervention. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.